61 results on '"Kaira K"'
Search Results
2. 1078P Correlation between T cell immunity and EGFR-TKI treatment in patients harboring EGFR driver mutation
3. 1067P Discovery of a new CD4+ T cell cluster that correlates PD-1 blockade efficacy
4. 411P Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
5. Unexpected response of extramedullary plasmacytoma in patients with lung cancer who received nivolumab
6. Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
7. P1.04-34 Efficacy and Safety of First-Line Pembrolizumab Monotherapy in Elderly Patients (Aged ≥ 75 years) with Non-Small Cell Lung Cancer
8. Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
9. EP1.01-83 Efficacy and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced NSCLC Harboring Sensitive EGFR Mutations
10. Abstract PD4-08: Relationship between FDG-uptake and expression level of PD-L1 in primary ER positive/HER2 negative breast cancer
11. P1.01-92 A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations
12. P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations
13. P3.01-43 Predictive Value of Computed Tomography Characteristics for Nivolumab Response in Pretreated Non-Small Cell Lung Cancer
14. P2.01-027 Clinical Significance of Topoisomerase-II Expression in Patients with Non-Small Cell Lung Cancer Treated with Amrubicin
15. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
16. P2.15-016 Clinical Significance of Topoisomerase-II Expression in Patients with Relapsed HGNEC of the Lung Treated with Amrubicin
17. P1.15-002 A Retrospective Study of Amrubicin Monotherapy for the Treatment of Relapsed Small Cell Lung Cancer in Elderly Patients
18. P2.15-005 Post-Progression Survival Is Strongly Linked to Overall Survival in Refractory Small-Cell Lung Cancer Patients Who Received Amrubicin
19. P2.02-026 Impact of PD-L1 Expression on 18F-FDG-PET in Pulmonary Squamous Cell Carcinoma
20. Endoplasmic reticulum stress in the pathogenesis of pretibial dystrophic epidermolysis bullosa
21. Prognostic impact of LAT1 and CD98 expression in cutaneous angiosarcoma
22. Expression of thymidylate synthase (TS) and its prognostic significance in patients with cutaneous angiosarcoma
23. 460P Phase I/II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL; TORG1424/OLCSG1402): results of the phase I part
24. 460P Phase I/II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL; TORG1424/OLCSG1402): results of the phase I part
25. Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma
26. Prognostic significance of GRP78/BiP expression in patients with Stage III/IV hypopharyngeal squamous cell carcinoma
27. Expression of ER stress markers (GRP78/BiP and PERK) in patients with tongue cancer
28. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
29. Recurrent intimal sarcoma mimicking pulmonary embolism
30. Detection of human papillomavirus ( HPV ) in patients with squamous cell carcinoma and the clinical characteristics of HPV ‐positive cases
31. P0143 ASC amino acid transporter 2 (ASCT2) as a novel prognostic marker in non-small-cell lung cancer
32. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer
33. Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer
34. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer
35. Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma
36. A Randomized Phase II Study of Axitinib Plus Pemetrexed/Cisplatin (PEM/CIS) for Non-Small-Cell Lung Cancer (NSCLC)
37. Prognostic Significance of L-Type Amino Acid Transporter 1 Expression in Completely Resected Pancreatic Cancer
38. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer
39. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer
40. 18F-FDG uptake on PET could be a predictive marker of Excision Repair Cross-Complementation Group 1 (ERCC1) expression in patients with thoracic neoplasms?
41. The prognostic impact of circulating tumor cells in patients with small cell lung cancer.
42. L-type Amino-acid Transporter 1 Expression Predicts the Response to Preoperative Hyperthermo-chemoradiotherapy for Locally Advanced Rectal Cancer
43. Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC).
44. The differential efficacy of docetaxel according to NSCLC histology and therapeutic effect of EGFR-TKIs.
45. Clinical significance of 18F-alpha-methyl tyrosine PET as a potential surrogate marker of LAT1 expression for predicting prognosis of non-small cell lung cancer.
46. 9036 The correlation of serial pro-gastrin-releasing peptide and neuron specific enolase with radiological response and overall survival of patients with small-cell lung cancer
47. Serial pro-gastrin-releasing peptide and neuron specific enolase in predicting radiological response and overall survival of patients with small-cell lung cancer
48. Can meta-analysis suggest carboplatin/paclitaxel as a reference arm in randomized trials of first-line chemotherapy for advanced non-small cell lung cancer?
49. The Monitoring of Serum Pro-Gastrin-Releasing Peptide (ProGRP) and Neuron-Specific Enolase (NSE) during Chemotherapy Is Useful for the Prognostic Assessment of Patients with Small-Cell Lung Cancer (SCLC).
50. Evaluation of the Safety and Compliance of 3-Week Cycles of Vinorelbine on Days 1 and 8 and Cisplatin on Day 1 as Adjuvant Chemotherapy in Japanese Patients with Completely Resected Pathological Stage IB to IIIA Non-small Cell Lung Cancer: A Retrospective Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.